Diabetes Care
Author:
Keywords:
Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, INITIAL COMBINATION THERAPY, GLYCEMIC CONTROL, OPEN-LABEL, INSULIN SENSITIVITY, PARALLEL-GROUP, VILDAGLIPTIN, TOLERABILITY, GLICLAZIDE, MELLITUS, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Exenatide, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Pioglitazone, Pyrazines, Sitagliptin Phosphate, Thiazolidinediones, Treatment Outcome, Triazoles, Venoms, DURATION-4 Study Group, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences
Abstract:
To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.